Evolus is a global performance beauty company that develops and commercializes medical aesthetic products sold directly to licensed practitioners who administer them to consumers paying out of pocket. The company's flagship product, Jeuveau®, is a proprietary botulinum toxin type A formulation for treating frown lines, while its Evolysse™ portfolio comprises injectable hyaluronic acid gels for mid-face, nasolabial folds, lips, and eye treatments. By focusing exclusively on non-reimbursed aesthetic products, Evolus avoids insurance-related regulatory burdens and gains flexibility for dynamic pricing and targeted marketing to practitioners, competing in the large and rapidly growing medical aesthetics market alongside established players and newer entrants offering neurotoxins and dermal fillers.